These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 15146408)

  • 1. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis.
    Landewé R; Geusens P; Boers M; van der Heijde D; Lems W; te Koppele J; van der Linden S; Garnero P
    Arthritis Rheum; 2004 May; 50(5):1390-9. PubMed ID: 15146408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study.
    Garnero P; Landewé R; Boers M; Verhoeven A; Van Der Linden S; Christgau S; Van Der Heijde D; Boonen A; Geusens P
    Arthritis Rheum; 2002 Nov; 46(11):2847-56. PubMed ID: 12428224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention.
    Landewé RB; Boers M; Verhoeven AC; Westhovens R; van de Laar MA; Markusse HM; van Denderen JC; Westedt ML; Peeters AJ; Dijkmans BA; Jacobs P; Boonen A; van der Heijde DM; van der Linden S
    Arthritis Rheum; 2002 Feb; 46(2):347-56. PubMed ID: 11840436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
    Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
    Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
    Charni N; Juillet F; Garnero P
    Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone.
    Korthals-de Bos I; Van Tulder M; Boers M; Verhoeven AC; Adèr HJ; Bibo J; Boonen A; Van Der Linden S
    J Rheumatol; 2004 Sep; 31(9):1709-16. PubMed ID: 15338488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysis.
    Landewé RB; Geusens P; van der Heijde DM; Boers M; van der Linden SJ; Garnero P
    Ann Rheum Dis; 2006 Jan; 65(1):40-4. PubMed ID: 16126801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs.
    Hashimoto J; Garnero P; van der Heijde D; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Yoshikawa H; Nishimoto N
    Mod Rheumatol; 2009; 19(3):273-82. PubMed ID: 19452245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
    Boers M; Verhoeven AC; Markusse HM; van de Laar MA; Westhovens R; van Denderen JC; van Zeben D; Dijkmans BA; Peeters AJ; Jacobs P; van den Brink HR; Schouten HJ; van der Heijde DM; Boonen A; van der Linden S
    Lancet; 1997 Aug; 350(9074):309-18. PubMed ID: 9251634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers.
    Young-Min S; Cawston T; Marshall N; Coady D; Christgau S; Saxne T; Robins S; Griffiths I
    Arthritis Rheum; 2007 Oct; 56(10):3236-47. PubMed ID: 17907159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial.
    ter Wee MM; den Uyl D; Boers M; Kerstens P; Nurmohamed M; van Schaardenburg D; Voskuyl AE; Lems WF
    Ann Rheum Dis; 2015 Jun; 74(6):1233-40. PubMed ID: 24818633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis.
    van Tuyl LH; Boers M; Lems WF; Landewé RB; Han H; van der Linden S; van de Laar M; Westhovens R; van Denderen JC; Westedt ML; Peeters AJ; Jacobs P; Huizinga TW; van de Brink H; Dijkmans BA; Voskuyl AE
    Ann Rheum Dis; 2010 May; 69(5):807-12. PubMed ID: 19451137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis.
    Boers M; Kostense PJ; Verhoeven AC; van der Linden S;
    Arthritis Rheum; 2001 Oct; 44(10):2242-6. PubMed ID: 11665964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial.
    van Tuyl LH; Lems WF; Voskuyl AE; Kerstens PJ; Garnero P; Dijkmans BA; Boers M
    Ann Rheum Dis; 2008 Nov; 67(11):1574-7. PubMed ID: 18625629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also 'disconnect' disease activity and damage in rheumatoid arthritis.
    Boers M; van Tuyl L; van den Broek M; Kostense PJ; Allaart CF
    Ann Rheum Dis; 2013 Mar; 72(3):406-9. PubMed ID: 23155223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy.
    Mullan RH; Matthews C; Bresnihan B; FitzGerald O; King L; Poole AR; Fearon U; Veale DJ
    Arthritis Rheum; 2007 Sep; 56(9):2919-28. PubMed ID: 17763421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial high-dose prednisolone combination therapy using COBRA and COBRA-light in early rheumatoid arthritis.
    Rasch LA; van Tuyl LH; Lems WF; Boers M
    Neuroimmunomodulation; 2015; 22(1-2):51-6. PubMed ID: 25227967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.
    Konijn NPC; van Tuyl LHD; Boers M; den Uyl D; Ter Wee MM; van der Wijden LKM; Bultink IEM; Kerstens PJSM; Voskuyl AE; van Schaardenburg D; Nurmohamed MT; Lems WF
    Rheumatology (Oxford); 2017 Sep; 56(9):1586-1596. PubMed ID: 28859326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression.
    Syversen SW; Goll GL; van der Heijde D; Landewé R; Gaarder PI; Odegård S; Haavardsholm EA; Kvien TK
    J Rheumatol; 2009 Feb; 36(2):266-72. PubMed ID: 19132792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial.
    Garnero P; Aronstein WS; Cohen SB; Conaghan PG; Cline GA; Christiansen C; Beary JF; Meyer JM; Bingham CO
    Osteoarthritis Cartilage; 2008 Jun; 16(6):660-6. PubMed ID: 17993283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.